TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s stock price has plunge by -6.96relation to previous closing price of 1.58. Nevertheless, the company has seen a 8.89% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-28 that The FDA clears TC BioPharm’s (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
Is It Worth Investing in TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) Right Now?
Additionally, the 36-month beta value for TCBP is 0.10. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of TCBP on April 25, 2024 was 4.65M shares.
TCBP’s Market Performance
The stock of TC BioPharm (Holdings) plc ADR (TCBP) has seen a 8.89% increase in the past week, with a 2.08% rise in the past month, and a -28.58% fall in the past quarter. The volatility ratio for the week is 9.38%, and the volatility levels for the past 30 days are at 13.99% for TCBP. The simple moving average for the past 20 days is -3.86% for TCBP’s stock, with a -75.01% simple moving average for the past 200 days.
TCBP Trading at 4.04% from the 50-Day Moving Average
After a stumble in the market that brought TCBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.41% of loss for the given period.
Volatility was left at 13.99%, however, over the last 30 days, the volatility rate increased by 9.38%, as shares surge +3.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.86% upper at present.
During the last 5 trading sessions, TCBP rose by +8.89%, which changed the moving average for the period of 200-days by -83.56% in comparison to the 20-day moving average, which settled at $1.5315. In addition, TC BioPharm (Holdings) plc ADR saw -53.63% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TCBP
Equity return is now at value -94.90, with -13.34 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.09.
Conclusion
In conclusion, TC BioPharm (Holdings) plc ADR (TCBP) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
